Fusion Genomics Corporation products

The ONETest Influenza EnviroScreen assay was developed for sensitive and scalable detection of influenza viruses in environmental samples. The assay is highly optimized for soil and wetland sediment samples from temperate regions, and can simultaneously identify and differentiate all 16 hemagglutinin and 9 neuraminidase subtypes. Thus, the assay can facilitate large-scale environmental screening for influenza viruses.

UNIPrep is the first component of our ONETest molecular diagnostics assay kit. It contains all the reagents (including QUANTUMProbes) to produce an enriched sequenceable library from a variety of sample sources (blood, nasal wash, NP swab, etc.) within 6 hours.

QUANTUMProbes, the second component of our ONETest molecular diagnostics assay kit, are comprised of synthetic non-reference based oligonucleotides designed using Fusion Genomics’ machine learning algorithms.

At the “Innovation Solutions Canada” the Canadian Government asked for solutions towards better detection and prevention of pandemics. Fusion Genomics took up this challenge and developed the ONETest Coronaviruses Plus Assay: a genomic capture assay to accurately and unambiguously diagnose human and animal coronaviruses, all known upper respiratory viruses. The assay when deployed can warn ahead about a potential second wave of COVID-19 (and other zoonotic pathogens) to detect any emerging and re-emerging viruses including SARS-CoV-2 at the human-animal interface.

The goal of personalized medicine is to achieve optimal therapy for each patient based on his or her genomic profile. In infectious or host-dependent diseases, this means therapies that also take into account the pathogen’s mutating genotype.